121 related articles for article (PubMed ID: 8874852)
1. Seroquel and cognitive improvement in patients with schizophrenia.
Stip E; Lussier I; Babai M; Fabian JL; Link C
Biol Psychiatry; 1996 Sep; 40(5):434-5. PubMed ID: 8874852
[No Abstract] [Full Text] [Related]
2. ICI 204,636: a new atypical antipsychotic drug.
Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
[No Abstract] [Full Text] [Related]
3. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
Nasrallah HA; Tandon R
J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142
[TBL] [Abstract][Full Text] [Related]
4. Effects of quetiapine on cognitive functions in schizophrenia.
Kivircik Akdede BB; Alptekin K; Kitiş A; Arkar H; Akvardar Y
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):233-8. PubMed ID: 15694229
[TBL] [Abstract][Full Text] [Related]
5. The effect of quetiapine on aggression and hostility in patients with schizophrenia.
Arango C; Bernardo M
Hum Psychopharmacol; 2005 Jun; 20(4):237-41. PubMed ID: 15830402
[TBL] [Abstract][Full Text] [Related]
6. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
[TBL] [Abstract][Full Text] [Related]
7. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
Kasper S
J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
[TBL] [Abstract][Full Text] [Related]
9. [Seroquel in a resistant schizophrenic with negative and positive symptoms].
Reznik I; Benatov R; Sirota P
Harefuah; 1996 May; 130(10):675-7, 727. PubMed ID: 8794656
[TBL] [Abstract][Full Text] [Related]
10. Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia.
Stip E; Fahim C; Mancini-Marïe A; Bentaleb LA; Mensour B; Mendrek A; Beauregard M
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):21-6. PubMed ID: 15610941
[TBL] [Abstract][Full Text] [Related]
11. Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series.
Pajonk FG; Schwertner AK; Seelig MA
J Psychopharmacol; 2006 Jan; 20(1):119-24. PubMed ID: 16204326
[TBL] [Abstract][Full Text] [Related]
12. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
13. Partial response to antipsychotic treatment: the patient with enduring symptoms.
Emsley RA
J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
[TBL] [Abstract][Full Text] [Related]
14. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.
Taniguchi T; Sumitani S; Aono M; Iga J; Kinouchi S; Aki H; Matsushita M; Taniguchi K; Tsuno M; Yamanishi K; Tomotake M; Kaneda Y; Ohmori T
Hum Psychopharmacol; 2006 Oct; 21(7):439-45. PubMed ID: 17029303
[TBL] [Abstract][Full Text] [Related]
15. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
Velligan DI; Miller AL
J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
17. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
[TBL] [Abstract][Full Text] [Related]
18. Effects of phenothiazines on anxiety and cognition in schizophrenia.
Meadow A; Donlon PT; Blacker KH
Dis Nerv Syst; 1975 Apr; 36(4):203-8. PubMed ID: 234827
[No Abstract] [Full Text] [Related]
19. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
[TBL] [Abstract][Full Text] [Related]
20. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta.
Sumiyoshi T; Higuchi Y; Itoh T; Matsui M; Arai H; Suzuki M; Kurachi M; Sumiyoshi C; Kawasaki Y
Psychiatry Res; 2009 Jun; 172(3):180-3. PubMed ID: 19386475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
